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G

rowth stimulation expressed gene 2 (ST2) is

prospective randomized controlled trial of

ABBREVIATIONS

a transmembrane protein and a member of

7,141 subjects presenting with signs and

AND ACRONYMS

the Toll-interleukin 1 receptor superfamily

symptoms

of

acute

decompensated

HF

CI = conﬁdence interval

(1,2). ST2 binds interleukin-33 in response to cardiac

comparing nesiritide (a recombinant B-type

disease or injury and elicits a cardioprotective effect

natriuretic peptide with vasodilatory prop-

by mitigating the maladaptive responses of the

erties) to placebo added to standard care. In

myocardium to overload states (3,4). A truncated sol-

our study cohort, 858 subjects (12% of the

IQR = interquartile range

uble form of ST2 (soluble ST2 [sST2]) competes with

total population) consented to participate in

NT-proBNP = aminoterminal

the membrane-bound form in this interleukin-33

the biomarker substudy. A large majority of

binding. Elevated levels of sST2 signal the presence

subjects in the biomarker substudy were

and severity of adverse cardiac remodeling and tissue

recruited from North American sites (n

HF = heart failure
HR = hazard ratio

pro–B-type natriuretic peptide

OR = odds ratio
sST2 = soluble growth
stimulation expressed gene 2

ﬁbrosis, which may occur in response to an acute

824). Compared to the rest of the North

coronary syndrome event or worsening heart failure

American study cohort (n

(HF) (3,5). Higher levels of sST2 are associated

differences in race (p

with more severe clinical symptoms and with other

atrial ﬁbrillation (p

objective measures of HF severity, such as higher

0.384), creatinine (p

C-reactive protein, higher natriuretic peptide levels,

(p

lower left ventricular ejection fraction, and higher

less, age (66.6  14.9 vs. 64.5  15.4 years, p

diastolic ﬁlling pressures (6–12). Elevated circulating

and left ventricular ejection fraction (31.6  15 vs.

sST2 levels have been associated with an increased

30.4  15, p

risk for mortality and sudden cardiac death in outpa-

STUDY DESIGN. The intent of the biomarker substudy

tients with HF (9,13–15), as well as in acute HF (16).

was to collect venous blood samples at randomization

However, most studies have only measured sST2

(“baseline”), 48 to 72 h following randomization, and

at a single timepoint (predominantly at baseline)

at the 30-day follow-up visit. Blood samples were

and only described the relationship with long-term

collected in ethylenediaminetetraacetic acid-plasma,

all-cause mortality.

immediately centrifuged at the study sites, and

2,419), there were no

0.422), heart rate (p

0.157),

0.124), blood urea nitrogen (p
0.499), time to randomization

0.051), or beta-blockers (p

0.073). Neverthe0.001)

0.035) were signiﬁcantly different.

In this post-hoc study utilizing blood specimens

stored at –80 C for subsequent analysis at a central

collected serially in the ASCEND-HF (Acute Study of

core laboratory. Aminoterminal pro–B-type natri-

Clinical Effectiveness of Nesiritide in Decompensated

uretic peptide (NT-proBNP) levels were determined

Heart Failure) trial, we examined the relationship

by the VITROS NT-proBNP Assay (Ortho-Clinical Di-

between baseline and serial levels of sST2 and dys-

agnostics, Raritan, New Jersey).

pnea status, hospitalization (at 30 days), and death
(at 180 days). We also examined the effect of nesiritide therapy on sST2 levels, hypothesizing that the
vasodilatory effects of nesiritide may relieve volume
overload more effectively than a placebo, thereby
potentially achieving greater reduction in sST2 levels.

METHODS

SOLUBLE

ST2

ASSAY. Plasma

sST2 levels were

measured by the Presage ST2 Assay (Critical Diagnostics, San Diego, California) at a College of
American Pathologists/Clinical Laboratory Improvements Amendments-approved core laboratory independent of the sponsors. This is a quantitative
sandwich enzyme-linked immunosorbent assay using
a mouse monoclonal antihuman sST2 capture anti-

STUDY POPULATION. Details

of the ASCEND-HF

body on microtiter plate wells and a second bio-

Trial (NCT00475852) have been described elsewhere

tinylated mouse monoclonal antihuman sST2 tracer

(17). Brieﬂy, this was a multinational, multicenter,

antibody with a measuring range of 3.1 to 200 ng/ml

and a coefﬁcient of variation <5%; the limit of

RESULTS

detection is at 1.8 ng/ml, and the limit of quantiﬁcaPATIENT CHARACTERISTICS. Baseline characteris-

tion at 2.4 ng/ml.
CLINICAL ENDPOINTS. The following adjudicated

tics of the study population are illustrated in Table 1.

endpoints were analyzed: 30-day death, 180-day

The median time between presenting to the hospital

death, 30-day HF hospitalization or death, and the

and randomization (baseline) was 16 h. In our study

composite of persistent or worsening HF or death from

cohort, median sST2 levels were 71.2 (IQR: 48.2 to

any cause. We also used the ASCEND-HF trial’s copri-

111.1) ng/ml at baseline, decreasing to 46.9 (IQR: 32.4

mary dyspnea endpoint (moderately or markedly

to 70.3) ng/ml at 48 to 72 h and 39.5 (IQR: 27.8 to 63.8)

improved relative to the time of randomization

ng/ml at 30 days. In other words, 89% (763 of 858) of

measured by a 7-point Likert-type scale at 6 or 24 h) to

patients had sST2 levels above the diagnostic cutoff

assess the association between sST2 levels and symp-

value of 35 ng/ml for chronic HF. Subjects with

tom relief.

impaired or preserved left ventricular ejection frac-

STATISTICAL ANALYSES. Clinical characteristics are

tion had similar levels of baseline sST2 (72.4 [IQR:

presented as a percentage (%) for categorical vari-

49.2 to 116.0] ng/ml vs. 68.9 [IQR: 45.1 to 108.3] ng/ml;

ables, mean  SD for normally distributed contin-

p

0.178, respectively).

uous variables, and median (interquartile range

BASELINE sST2 LEVELS AND PROGNOSIS. There

[IQR]) for non-normally distributed continuous var-

were 24 (2.8%) deaths and 77 (9.2%) HF rehospitali-

iables. The Cochran-Armitage test was used to test

zations by 30 days, and 97 (11.4%) deaths by 180 days.

for trend in baseline characteristics across increasing

Higher baseline sST2 level was associated with a

tertiles of sST2 at baseline. Survival curves are

higher risk of death at 30 days (OR: 2.33; 95% conﬁ-

estimated for each group, considered separately,

dence interval [CI]: 1.05 to 5.19; p

using the Kaplan-Meier method and compared sta-

180 days (HR: 2.21; 95% CI: 1.56 to 3.13; p < 0.001),

tistically using the log-rank test. The association

as well as death/worsening HF before discharge

between sST2 and outcomes was performed using

(OR: 2.23; 95% CI: 1.28 to 3.90; p

both univariate and multivariate logistic regression

Figure 1A shows that increasing quartiles of baseline

analysis (for 30-day outcomes) or Cox proportional

sST2 was associated with greater 180-day mortality

hazards analysis (for 180-day mortality). Logistic

risk by Kaplan-Meier estimates. In contrast, symp-

regression was used in the analyses of dyspnea

tomatic relief at 6 h and at 24 h was not associated

improvement. sST2 and NT-proBNP were both log

with higher levels of baseline sST2 (p > 0.29, data not

transformed, and odds ratios (ORs) and hazard ra-

shown). After adjusting for other risk covariates in the

tios (HRs) were analyzed using increments of sST2/

ASCEND-HF risk model, only 180-day mortality risk

NT-proBNP per log increase in sST2. For the multi-

was associated with higher levels of baseline sST2

variate analysis, we adjusted the covariates identi-

(adjusted HR: 1.79; 95% CI: 1.22 to 2.62; p

ﬁed from the overall ASCEND-HF study population

(Table 2). However, further adjustment with the

to

ASCEND-HF

ASCEND-HF risk model plus baseline NT-proBNP

risk model) (Online Table 1). We used the robust

levels demonstrated that the prognostic value of

be

prognostically

relevant

(the

0.038) and at

0.005) (Table 2).

0.003

covariance matrix estimates to adjust the variance-

baseline sST2 was no longer signiﬁcant (Table 2, as

covariance matrix of both logistic regression and

dichotomous variables in Online Table 2); this was

Cox models to correct for correlated responses from

true despite the fact that adding baseline sST2 to the

cluster (multicenter) samples (18). To assess if the

ASCEND-HF risk model, plus baseline NT-proBNP,

addition of sST2 to the ASCEND-HF risk model with

correctly reclassiﬁed 10.76% of subjects for the

NT-proBNP improves outcome prediction, we used

180-day death endpoint (with 8.64% events correctly

the category-free net reclassiﬁcation index by the

classiﬁed and 2.12% nonevents correctly classiﬁed)

Pencina method (19,20). Levels of sST2 at all time

(Online Table 3A). Interestingly, interaction testing

points and changes in sST2 from baseline were

between baseline sST2 and baseline NT-proBNP

compared between subjects receiving nesiritide and

was statistically signiﬁcant only for the 30-day

placebo using the Wilcoxon rank sum test or Stu-

death/HF rehospitalization endpoint in both unad-

dent t test. All statistical analyses were performed

justed (p

using Stata 13.1 software (StataCorp LP, College

(Online Table 4). Speciﬁcally, there was a positive

Station, Texas) and R 3.1.0 (Vienna, Austria). A

association between baseline sST2 and outcomes for

2-sided p value of <0.05 was considered statistically

high (above median) baseline NT-proBNP, and a

signiﬁcant.

negative association between sST2 and outcomes for

0.03) and adjusted (p

0.02) models

F I G U R E 1 Kaplan-Meier Analysis for 180-Day Survival

Kaplan Meier analysis for 180 day survival, stratiﬁed by quartiles of (A) baseline and (B) 48 to 72 h follow up plasma soluble growth stimulation expressed gene 2
(sST2) levels. Baseline sST2 tertile ranges: Quartile 1 (Q1)
48 to 72 h sST2 tertile ranges: Quartile 1

<48.2 ng/ml; Quartile 2

<32.4 ng/ml; Quartile 2

48.2 to 71.2 ng/ml; Quartile 3

32.4 to 46.8 ng/ml; Quartile 3

71.3 to 111.2 ng/ml; Quartile 4

46.9 to 70.3 ng/ml; Quartile 4

>111.2 ng/ml.

>70.3 ng/ml.

the 180-day mortality risk for baseline sST2 levels

CHANGES IN sST2 LEVELS AND PROGNOSIS. Among

(Figure 2A).

the 858 subjects in the biomarker substudy, 680 had
samples for both baseline and 48 to 72 h time points.

FOLLOW-UP sST2 LEVELS AND PROGNOSIS. At 48

Compared to baseline, an overall 64.4% and 51.6%

to 72 h after enrollment, higher sST2 levels portend

reduction in absolute levels of sST2 levels occurred at

increased risk of all-cause death at both 30 and 180

48 to 72 h and at 30 days after randomization,

days, as well as death/rehospitalization at 30 days

respectively. The median absolute change in sST2

(Table 2). Elevated follow-up sST2 was also associated

from baseline to 48 to 72 h was –22.80 (IQR: –44.70 to

with increased risk of death/worsening HF before

–6.44) ng/ml. At 48 to 72 h, there was no lowering of

discharge (OR: 2.41; 95% CI: 1.25 to 4.63; p

0.008).

sST2 absolute levels from baseline in 14.4% of sub-

After adjustments for the ASCEND-HF risk model,

jects; this was associated with poorer outcomes,

the prognostic signiﬁcance of follow-up sST2 levels

including 30-day death/HF readmission (OR: 2.50;

was only relevant for 180-day death, and remained

95% CI: 1.45 to 4.32; p

borderline signiﬁcant with the addition of baseline

(HR: 1.98; 95% CI: 1.15 to 3.42; p

NT-proBNP to the ASCEND-HF risk model (adjusted

compared with subjects showing any decrease in

HR: 1.61; 95% CI: 1.00 to 2.60; p

0.001) and 180-day death
0.013) when

0.051) (Table 2).

sST2 (Figure 3). After adjustments for the ASCEND-

Examining the Kaplan-Meier curves revealed that

HF risk model and baseline NT-proBNP, the prog-

the divergence of 180-day mortality risk occurred

nostic value of the lack of sST2 lowering at 48 to 72

between the third and fourth quartile of the 48- to

h from baseline was signiﬁcant for the outcome of

72-h follow-up sST2 level (71.2 ng/ml). Furthermore,

30-day death/HF readmission (adjusted OR: 1.94;

adding 48- to 72-h follow-up sST2 to the ASCEND-HF

95% CI: 1.01 to 3.72; p

risk model, plus follow-up NT-proBNP, correctly

180-day death endpoint (adjusted HR: 1.27; 95% CI:

0.046), but not for the

reclassiﬁed 15.6% of subjects for the 180-day death

0.69 to 2.35; p

endpoint (with 13.85% events correctly classiﬁed

biologic/analytic variability for sST2 has been pre-

and 1.75% nonevents correctly classiﬁed; Online

viously reported as w30% (21,22), we further de-

0.442). Because the combined

Table 3B). Cubic spline analyses supported the line-

ﬁned a clinically relevant sST2 reduction as a >30%

arity of the risk at follow-up (Figure 2B). In addition,

decrease in sST2 levels from baseline to 48 to 72 h

30-day follow-up sST2 levels also provide incre-

(which occurred in 377 subjects, or 55%). Compared

mental prognostic value in either of the adjusted

to those with a #30% sST2 reduction, subjects who

models (Table 2, Online Figure 3), with similar

demonstrated a >30% reduction in sST2 had lower

modest reclassiﬁcation to the 48- to 72-h follow-up

event rates in all endpoints except for 30-day death

data (Online Table 3C).

(Online Figure 4).

CHANGES IN sST2 LEVELS AND TREATMENT. Over-

F I G U R E 2 Cubic Spline Curve

all, 502 subjects (257 assigned to nesiritide, 245
assigned to placebo) had samples collected at all 3
time points. There were no signiﬁcant differences in
baseline characteristics between the nesiritide and
placebo treatment groups, including similar mean
NT-proBNP levels (8,910  10,492 pg/ml vs. 8,968 
9,577 pg/ml; p

0.329). Both groups demonstrated a

signiﬁcant reduction in sST2 levels from baseline to
48- to 72-h follow-up, and further lowering of sST2
levels was observed at the 30-day visit in both groups
(Table 4). The absolute changes in sST2 from baseline to 48 to 72 h was signiﬁcantly greater in the
placebo group than in the nesiritide group (respective
median absolute changes –26.11 ng/ml vs. –18.05 mg/l;
p

0.005), but the 2 groups did not differ by treat-

ment regarding absolute changes in sST2 from baseline to 30 days (Table 4). Additionally, sST2 levels at
30-day follow-up and absolute changes in sST2 levels
from baseline to 30 days were similar between the 2
treatment groups (Table 4).

DISCUSSION
There are 4 major ﬁndings from this study. First, we
observed that baseline sST2 levels elevated in the
acute HF setting were comparable with earlier reports (23–26), and were higher than those reported
in the chronic setting (cutoff at 35 ng/ml) (9,15).
Second, the prognostic ﬁndings for sST2 at baseline
for 180-day outcomes were generally neutral after
adjustments for the ASCEND-HF risk model and
NT-proBNP, despite the signiﬁcant univariate ﬁndCubic spline curve for (A) baseline; and (B) follow up (48 to 72 hr)
sST2 levels associated with 180 day death. sST2

soluble growth

stimulation expressed gene 2.

ings. In contrast, follow-up (48 to 72 h or 30 days)
sST2 appeared to provide incremental prognostic
value, albeit diminished following covariate and
NT-proBNP

adjustments.

Third,

consistent

with

previous reports sST2 levels tend to fall after medTo further examine whether there is a threshold of

ical therapy (23,27,28), but we found that 1 in 7

follow-up sST2 level that conferred heightened risk,

patients

Online Table 5 outlines the baseline characteristics

following medical therapy. Meanwhile, persistently

demonstrated

no

fall

in

sST2

levels

of subgroups according to changes from baseline to

elevated sST2 levels (above baseline median of 71.2

48- to 72-h sST2 levels, stratiﬁed at a baseline median

ng/ml), or lack of any lowering of sST2 levels

sST2 level of 71.2 ng/ml (Online Figure 5 presents the

despite medical therapy, may deﬁne a higher-risk

CONSORT diagram for subgroup distributions). In the

subset of patients compared to those who demon-

cohort with elevated baseline sST2 levels (>71.2 ng/ml),

strated a fall in sST2 level following medical ther-

we further observed a 3-fold increase in 180-day mor-

apy as seen in a smaller series (23). Finally, contrary

tality risk between those with persistently high sST2

to our hypothesis, nesiritide did not demonstrate

(>71.2 ng/ml) versus low (#71.2 ng/ml) at 48- to 72-h

any signiﬁcant effects on lowering sST2 levels over

follow-up (Figure 4, also Online Figure 6 for all sub-

standard therapy in the long-term. Conversely, the

groups); this ﬁnding remained statistically signiﬁcant

placebo group showed a greater fall in sST2 levels

in multivariate analysis after adjusting for the

from baseline to 48 to 72 h than the nesiritide

ASCEND-HF risk model and baseline NT-proBNP

group, even though such difference did not extend

(Table 3).

to the 30-day timepoint. Therefore, persistently

F I G U R E 3 Comparison of Adverse Clinical Outcomes

Comparison of adverse clinical outcomes in patients with a decrease versus increase/no change in absolute levels of sST2. HF
sST2

heart failure;

soluble growth stimulation expressed gene 2.

elevated sST2 following stabilization during acute

unexpected, because previous studies have demon-

HF hospitalization may identify a higher risk cohort

strated an incremental prognostic value of sST2

even after clinical risk factors and NT-proBNP levels

levels—even when adjusting for the levels of various

have been considered.

natriuretic peptide assays (6,16,29). Although there

The lack of incremental prognostic signiﬁcance

are some inconsistencies between the Cox models

of baseline sST2 with the addition of NT-proBNP

and the reclassiﬁcation analysis, it has been increas-

levels to the standard ASCEND-HF risk model was

ingly recognized that the latter may in some cases

F I G U R E 4 Serial sST2 Levels and Adverse Clinical Outcomes

Kaplan Meier survival analysis stratiﬁed by high versus low baseline and follow up (48 to 72 h) sST2 levels (cutoff at 71.2 ng/ml), excluding the
small subset of subjects with low sST2 at baseline and elevated sST2 at follow up (n

15).
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